S
Satawat Thongsawat
Researcher at Chiang Mai University
Publications - 74
Citations - 3936
Satawat Thongsawat is an academic researcher from Chiang Mai University. The author has contributed to research in topics: Hepatitis B & Telbivudine. The author has an hindex of 22, co-authored 72 publications receiving 3632 citations. Previous affiliations of Satawat Thongsawat include Institut de recherche pour le développement.
Papers
More filters
Journal ArticleDOI
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
George K. K. Lau,Teerha Piratvisuth,Kang Xian Luo,Patrick Marcellin,Satawat Thongsawat,Graham Cooksley,Edward Gane,Michael W. Fried,Wan Cheng Chow,Seung Woon Paik,Wen Yu Chang,Thomas Berg,Robert Flisiak,Philip McCloud,Nigel Pluck +14 more
TL;DR: In patients with H beAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression, and HBsAg serconversion.
Journal ArticleDOI
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Ching-Lung Lai,Edward Gane,Yun-Fan Liaw,Chao-Wei Hsu,Satawat Thongsawat,Yuming Wang,Yagang Chen,E. Jenny Heathcote,Jens Rasenack,Natalie Bzowej,Nikolai V. Naoumov,Adrian M. Di Bisceglie,Stefan Zeuzem,Young Myoung Moon,Zachary Goodman,George C. Chao,Barbara Fielman Constance,Nathaniel A. Brown +17 more
TL;DR: Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patientstreated with lamivudines.
Journal ArticleDOI
Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B
Gonzague Jourdain,Nicole Ngo-Giang-Huong,Linda Harrison,Luc Decker,Woottichai Khamduang,Camlin Tierney,Nicolas Salvadori,Tim R. Cressey,Wasna Sirirungsi,Jullapong Achalapong,Prapap Yuthavisuthi,Prateep Kanjanavikai,Orada P. Na Ayudhaya,Thitiporn Siriwachirachai,Sinart Prommas,Prapan Sabsanong,Aram Limtrakul,Supang Varadisai,Chaiwat Putiyanun,Pornnapa Suriyachai,Prateung Liampongsabuddhi,Suraphan Sangsawang,Wanmanee Matanasarawut,Sudanee Buranabanjasatean,Pichit Puernngooluerm,Chureeratana Bowonwatanuwong,Thanyawee Puthanakit,Virat Klinbuayaem,Satawat Thongsawat,Sombat Thanprasertsuk,George K. Siberry,D. H. Watts,Nahida Chakhtoura,Trudy V. Murphy,Noele P. Nelson,Raymond T. Chung,Stanislas Pol,Nantasak Chotivanich +37 more
TL;DR: In a setting in which the rate of mother‐to‐child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg‐positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.
Journal ArticleDOI
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine
Ching-Lung Lai,E.J. Gane,C.-W. Hsu,Satawat Thongsawat,Yuming Wang,Yagang Chen,EJ Heathcote,Jens Rasenack,Natalie Bzowej,Nikolai V. Naoumov,S. Zeuzem,A. M. Di Bisceglie,George C. Chao,A Barbara,F Constance,Nathaniel A. Brown +15 more
Journal ArticleDOI
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study
Christophe Moreno,Thomas Berg,Tawesak Tanwandee,Satawat Thongsawat,Hans Van Vlierberghe,Stefan Zeuzem,Oliver Lenz,Monika Peeters,Vanitha Sekar,Goedele De Smedt +9 more
TL;DR: The results of this phase IIa proof-of-concept trial provide evidence that TMC435 has a spectrum of activity against multiple HCV genotypes, except for genotype 3.